Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, ADMA Biologics's Enterprise Value is $2,285.3 Mil.
ADMA Biologics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $136.7 Mil. Therefore, ADMA Biologics's EV-to-OCF for today is 16.71.
The historical rank and industry rank for ADMA Biologics's EV-to-OCF or its related term are showing as below:
ADMA'
s EV-to-OCF Range Over the Past 10 Years
Min: -70.19 Med: -3.05 Max: 179.73
Current: 16.71
During the past 13 years, the highest EV-to-OCF of ADMA Biologics was 179.73. The lowest was -70.19. And the median was -3.05.
ADMA's EV-to-OCF is ranked worse than 87.3% of 1409
companies
in the Biotechnology industry
Industry Median: -3.48
vs ADMA: 16.71
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ADMA Biologics's PE Ratio (TTM) for today is calculated as:
ADMA Biologics's share price for today is $9.89.
ADMA Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.700.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ADMA Biologics EV-to-OCF Related Terms
ADMA Biologics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for ADMA Biologics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ADMA Biologics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's EV-to-OCF falls into.
ADMA Biologics's current Enterprise Value is $2,285.3 Mil.
ADMA Biologics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $136.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA Biologics (ADMA) has a EV-to-OCF of 16.71 as of Aug. 08, 2026. According to the industry distribution chart, ADMA Biologics ranks #1230 out of 1409 companies in the Biotechnology industry, placing it in the top 87.3%.
Is ADMA Biologics' EV-to-OCF too high?
ADMA Biologics' current EV-to-OCF is 16.71. Based on the distribution chart, ADMA Biologics ranks #1230 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ADMA Biologics has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' EV-to-OCF compare to ZBIO and PGEN?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #1230 out of 1409 companies for EV-to-OCF. This places ADMA Biologics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. ADMA Biologics's current EV-to-OCF is 16.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.23, compared to a current price of $9.89 — trading 45.7% below its estimated fair value. The current EV-to-OCF is 16.71. ADMA Biologics' overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current EV-to-OCF is 16.71 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $9.89 is trading 45.7% below its estimated GF Value™ of $18.23.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
EV-to-OCF: 16.71
GF Value™: $18.23 vs. price of $9.89 (45.7% below fair value)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
68GF Score
Get the complete analysis for ADMA
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
